Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
22 lutego 2013 zaktualizowane przez: Bristol-Myers Squibb
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI)
The purpose of this study is to determine whether exemestane plus dasatinib will be well-tolerated and will increase progression-free survival (PFS) in the treatment of advanced estrogen-receptor positive (ER+) breast cancer after disease progression (PD) on a non-steroidal aromatase inhibitor (NSAI).
Przegląd badań
Status
Status
Zakończony
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
Zapisy
155
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Lille, Francja, 59000
- Local Institution
-
Paris Cedex 13, Francja, 75651
- Local Institution
-
Saint-Cloud Cedex, Francja, 92211
- Local Institution
-
-
-
-
-
Madrid, Hiszpania, 28041
- Local Institution
-
Madrid, Hiszpania, 28033
- Local Institution
-
Torrevieja, Hiszpania, 03186
- Local Institution
-
-
-
-
-
Dublin, Irlandia, 24
- Local Institution
-
-
-
-
-
Gdansk, Polska, 80-952
- Local Institution
-
Gdansk, Polska, 80-462
- Local Institution
-
Lodz, Polska, 93-509
- Local Institution
-
Opole, Polska, 45-060
- Local Institution
-
-
-
-
-
Hradec Kralove, Republika Czeska, 500 05
- Local Institution
-
Prague 5, Republika Czeska, 150 06
- Local Institution
-
-
-
-
California
-
Fountain Valley, California, Stany Zjednoczone, 92708
- Compassionate Cancer Care Medical Group, Inc
-
Riverside, California, Stany Zjednoczone, 92501
- Compassionate Cancer Care Medical Group Inc
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19106
- Pennsylvania Oncology/Hematology Associates
-
-
Tennessee
-
Memphis, Tennessee, Stany Zjednoczone, 38120
- The West Clinic
-
-
-
-
-
Vasteras, Szwecja, 72189
- Local Institution
-
-
-
-
Essex
-
Chelmsford, Essex, Zjednoczone Królestwo, CM1 7ET
- Local Institution
-
-
Greater London
-
London, Greater London, Zjednoczone Królestwo, NW1 2BU
- Local Institution
-
-
Warwickshire
-
Coventry, Warwickshire, Zjednoczone Królestwo, CV22DX
- Local Institution
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Histologically-documented invasive estrogen receptor positive breast cancer , with tumor tissue from prior surgery available for analysis
- Prior therapy with a non-steroidal aromatase inhibitor
- Recurrent or progressive advanced breast cancer (locally-advanced or metastatic)
- Documented breast cancer with tumor ≤ 28 days prior to study entry
- Women who are NOT of childbearing potential
- Must be able to take oral medication
- Performance Status 0 or 1
Exclusion Criteria:
- Pleural or pericardial effusion or ascites (of any etiology; Grade ≥ 1) within 6 months prior to study entry
- Any chemotherapy, immunotherapy < 6 months before study entry. Any targeted therapy (eg. lapatinib) < 6 months before study entry, unless given in combination with an NSAI
- Any antitumor therapy, including radiotherapy or hormonal therapy, within 15 days prior to study entry
- Prior exposure to exemestane, any Src-family kinase inhibitor including dasatinib, to agents intended to control osteolytic disease other than bisphosphonates, or to any investigational agent for breast cancer
- Concurrent or previous malignant disease requiring chemotherapy or radiation treatment within the prior 3 years
- Significant bleeding disorder, or ongoing or recent clinically-significant gastrointestinal bleeding
- Any serious cardiac condition, including congestive heart failure or myocardial infarction within 6 months, uncontrolled angina, or Class III or IV heart disease as defined by the New York Heart Association, baseline ejection fraction ≤ 40%, diagnosed congenital long QT syndrome, clinically-significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes), QTc interval > 450 msec at baseline (Fridericia correction)
- Hematologic abnormality Grade ≥ 2
- Hypocalcemia of Grade ≥ 1
- Any Chemistry abnormality of Grade ≥ 2 [except Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease]
- Pregnant Women and Women of Childbearing Potential (WOCBP)
- Extremely lactose intolerant, in the judgment of treating physician (100 mg dasatinib contains 135 mg lactose, posing a problem only if intolerance is severe)
- Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Subjects must discontinue drug use at least 7 days prior to starting dasatinib)
- Potent inhibitors of CYP3A4 isoenzyme
- Prisoners or subjects who are involuntarily incarcerated; or subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
2
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Aktywny komparator: A
|
Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
Inne nazwy:
|
|
Komparator placebo: B
|
Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression Free Survival (PFS) Distribution for Exemestane Plus Dasatinib vs Exemestane Plus Placebo
Ramy czasowe: Prior to study therapy, at 8 week intervals until progression occurs (maximum participant PFS of 71 weeks)
|
PFS= The time (weeks) from date of randomization to date of progressive disease(PD).
PFS for each randomization arm was estimated using the Kaplan-Meier product-limit method.
A point estimate and a 95% confidence interval (CI) for the median PFS was computed for each randomization arm using the Brookmeyer & Crowley method.
PD=Increase (≥ 20%) in sum of longest diameters from smallest value during study (including baseline).
|
Prior to study therapy, at 8 week intervals until progression occurs (maximum participant PFS of 71 weeks)
|
|
Participants With Disease Progression or Death for Exemestane Plus Dasatinib vs Exemestane Plus Placebo
Ramy czasowe: Prior to study therapy, at 8 week intervals until progression occurs. Maximum participant PFS of ____ months)
|
PD is an increase (≥ 20%) in sum of longest diameters from smallest value during study (including baseline).
|
Prior to study therapy, at 8 week intervals until progression occurs. Maximum participant PFS of ____ months)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Participants With Best Overall Response
Ramy czasowe: at 6 months
|
Complete response (CR) = Disappearance of all measurable and non-measurable lesions, and no new lesions; Partial response (PR) = Decrease ≥30% from baseline in sum of longest diameters (LD) of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions.
SD = Disease re-assessment not qualifying as CR, PR or PD(≥20% increase in sum of longest diameters from smallest value).
|
at 6 months
|
|
Percentage of Participants With Clinical Benefit (CB) for Exemestane Plus Dasatinib Arm vs Exemestane Plus Placebo Arm at 6 Months
Ramy czasowe: at 6 months
|
CB = participants whose best response is CR, PR, or stable disease(SD).
CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease ≥30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions.
SD = Disease re-assessment not qualifying as CR, PR or PD(≥20% increase in sum of longest diameters from smallest value).
Confidence interval computed by Clopper-Pearson method.
|
at 6 months
|
|
Percentage of Participants With Response in Exemestane Plus Dasatinib Arm and Exemestane Plus Placebo Arms
Ramy czasowe: Prior to study therapy, at 8 week intervals until progression occurs (maximum participant response was 39 weeks)
|
Response= Proportion of response-evaluable participants whose best response is CR or PR.
Confidence intervals was computed using the Clopper-Pearson method.
CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease ≥30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions.
|
Prior to study therapy, at 8 week intervals until progression occurs (maximum participant response was 39 weeks)
|
|
Participants With Freedom-From-Progression (FFP) at 6 Months
Ramy czasowe: at 6 months
|
FFP at month 6 is defined for the randomized participants who had the probability of neither progressing nor dying before 6 months.
|
at 6 months
|
|
Time to Response for Exemestane Plus Dasatinib Arm and Exemestane Plus Placebo Arms
Ramy czasowe: Prior to study therapy, at 8 week intervals until CR or PR. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug, whichever is longer
|
Time to response is defined as time from first dose of study therapy until measurement criteria are first met for PR or CR (whichever is recorded first).
CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease ≥30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions.
|
Prior to study therapy, at 8 week intervals until CR or PR. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug, whichever is longer
|
|
Duration of Response for Exemestane Plus Dasatinib Arm and Exemestane Plus Placebo Arms
Ramy czasowe: Prior to study therapy, at 8 week intervals. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug, whichever is longer.
|
Duration of response is defined as the time from date that measurement criteria are first met for PR or CR until first date of documented PD or death.
CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease ≥30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions.
PD=Increase (≥ 20%) in sum of longest diameters from smallest value during study (including baseline).
|
Prior to study therapy, at 8 week intervals. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug, whichever is longer.
|
|
Changes in Participant-reported Pain Intensity in Participants With Bone Metastasis
Ramy czasowe: Start of study, at treatment start, after 2, 4, and 8 weeks of therapy and every 8 weeks thereafter, at end-of-treatment. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug.
|
Pain intensity evaluated by administration of the Brief Pain Inventory - Short Form (BPI-sf).
The BPI-sf is a psychometrically-validated instrument which measures both pain severity and functional interference caused by pain using an 11-point numerical rating scale.
Severity of pain at its "worst", "least" and "on average" in the last 24 hours, and "right now" (ie, at the time the questionnaire is being filled out) is recorded using anchors of "no pain" = "0" and "pain as bad as you can imagine" = "10".
|
Start of study, at treatment start, after 2, 4, and 8 weeks of therapy and every 8 weeks thereafter, at end-of-treatment. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug.
|
|
Changes in Markers of Bone Lysis in Participants With Bone Metastasis
Ramy czasowe: Screening, Day 1, after week 2, 4, and week 8 and subsequently every 8 weeks, at end-of-treatment. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug.
|
Assay for urinary N-telopeptide was used to evaluate Osteolytic activity.
|
Screening, Day 1, after week 2, 4, and week 8 and subsequently every 8 weeks, at end-of-treatment. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug.
|
|
Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs (as Per National Cancer Institute [NCI] Common Toxicity Criteria for Adverse Events [CTCAE], Version 3.0)
Ramy czasowe: From start of study drug therapy up to 30 days after the last dose. Median duration of therapy (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.
|
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug.
SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose.
Participants who discontinued the study due to any AEs were recorded.
Grade (GR)1 = mild, GR 2 = moderate, GR 3=severe, GR 4=life threatening, GR 5=death.
|
From start of study drug therapy up to 30 days after the last dose. Median duration of therapy (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.
|
|
Number of Participants With Grade 1-4 Hematology Abnormalities (as Per the NCI CTCAE, Version 3.0)
Ramy czasowe: Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.
|
Abnormalities were graded per NCI-CTC, Version 3.0 criteria.
Grade (GR)1 = mild, GR 2 = moderate, GR 3 = severe, GR 4 = life threatening.
Normal ranges are provided by the Local Laboratory and may vary according to sex and age.
Granulocytes, GR 1;<LLN-1.5x
10^9/L, GR 2:<1.5-1.0x10^9/L,
GR 3: <1.0 - 0.5x10^9/L, GR, 4: <0.5x10^9 /L; Hemoglobin, GR 1: <LLN-10.0
g/dL, GR 2: <10.0-8.0 g/dL, GR 3: <8.0-6.5 g/dL, GR, 4: <6.5g/dL; Platelets, GR 1: <LLN-75.0x10^9/L,
GR 2: <75.0-50.0x10^9/L,
GR 3: <50.0-25.0x10^9/L;
Leukocytes, GR 1: <LLN-3.0x10^9/L,
GR 2: <3.0-2.0x10^9/L,
GR 4: <1.0x10^9/L.
|
Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.
|
|
Number of Participants With Grade 1-4 Serum Chemistry Abnormalities in Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Bilirubin, Calcium, Creatinine, and Albumin (as Per the NCI CTCAE, Version 3.0)
Ramy czasowe: Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.
|
Grade (GR) 1 = mild, GR 2 = moderate, GR 3 = severe, GR 4 = life threatening).
Normal ranges are provided by the Local Laboratory and may vary according to sex and age.
Alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, GR 1: >ULN-2.5 x ULN (upper limit of normal), GR 2: >2.5-5.0 x ULN, GR 3: 5.0-20.0
x ULN; Low calcium, GR 1: <LLN - 8.0 mg/dL, GR 2: <8.0-7.0 mg/dL, GR 4:<6.0 mg/dL; High calcium, GR 1:>ULN - 11.5 mg/dL; bilirubin, GR 1: >ULN-1.5 x ULN,GR 3: >3-10 x ULN; Creatinine, GR1:>ULN-1.5 x ULN, GR2: >1.5-3.0 x ULN; Albumin, GR1:<LLN-3 g/dL,GR2:<3-2 g/dL.
|
Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.
|
|
Number of Participants With Grade 1-4 Serum Chemistry Abnormalities in Potassium, Magnesium, Sodium, Phosphorous, Uric Acid, and Bicarbonate (as Per the NCI CTCAE, Version 3.0)
Ramy czasowe: Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.
|
Grade (GR)1= mild, GR2= moderate, GR3= severe, GR4= life threatening.
Ranges are provided by the local laboratory and may vary according to sex and age.
Phosphorous, GR1:<LLN 2.5 mg/dL, GR2:<2.5-2.0 mg/dL, GR3: 1.0-<2.0
mg/dL; Low sodium,GR1:<LLN 130mmol/L, GR3:120-<130 mmol/L; High Magnesium, GR1 >ULN 3.0 mg/dL,GR 3:<0.3 0.8mg/dL; Uric acid, GR1:>ULN 10 mg/dL, GR4:>10 mg/dL; Low potassium, GR1:<LLN 3.0mmol/L,GR3:<3.0
2.5mmol/L; High potassium, GR1:>ULN-5.5 mmol/L, GR2:>5.5-6.0 mmol/L; Bicarbonate, GR1:<LLN-16 mmol/L; GR2:<16 - 11 mmol/L; Hig sodium, GR1:>ULN-150 mmol/L,GR2:>150-155 mmol/L.
|
Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.
|
|
Number of Participants With Abnormalities in Vital Signs
Ramy czasowe: Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment.
|
Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment.
|
|
|
Number of Participants With Abnormalities in Electrocardiograms
Ramy czasowe: Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment.
|
Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment.
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Sponsor
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Przydatne linki
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
Rozpoczęcie studiów
1 lutego 2009
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
1 marca 2011
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
1 grudnia 2012
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
6 października 2008
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
6 października 2008
Pierwszy wysłany (Oszacować)
Pierwszy wysłany
7 października 2008
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia wysłana aktualizacja
28 lutego 2013
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
22 lutego 2013
Ostatnia weryfikacja
Ostatnia weryfikacja
1 lipca 2012
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby skórne
- Nowotwory
- Nowotwory według lokalizacji
- Choroby piersi
- Nowotwory piersi
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Inhibitory enzymów
- Środki przeciwnowotworowe
- Hormony, substytuty hormonów i antagoniści hormonów
- Inhibitory kinazy białkowej
- Antagoniści hormonów
- Inhibitory aromatazy
- Inhibitory syntezy sterydów
- Antagoniści estrogenu
- Eksemestan
- Dazatynib
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- CA180-261
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .